11/03/2011
ReGen Therapeutics Limited (‘ReGen’ or the ‘Company’) has today appointed MBM Partners to assist it in the development of a distribution network for its nutraceutical product ColostrininTM in the countries of the Middle East and North Africa (MENA#).
MBM Partners was set up in 2006 and is based in London. It represents a number of European companies in the distribution of their brands in the health and personal care sectors across the Middle East & North Africa region. The company works with the leading distributors in the region. These have been carefully selected for their expertise in the distribution of brands in this sector.
MBM Partners aims to introduce the ColostrininTM opportunity to potential distributors and licensees in the region beginning with those in its current network. The initial focus will be to appoint distribution partners in the most important local markets. Thereafter smaller markets will be targeted.
MBM Partners will be responsible for product registration and working closely with appointed distributors and licensees at both the strategic and operational level to ensure the success of the ColostrininTM brand.
Commenting on this appointment Tim Shilton, ReGen CEO said: ‘This tie-up with MBM will hopefully lead to the distribution of Colostrinin within several markets in this currently untapped area. Working with a company that already has a network of established distributors and experience in getting products like Colostrinin marketed in the region should make this process more efficient’.
To date ColostrininTM is marketed as a nutritional supplement to ‘support healthy brain aging and cognition in humans’ in the US, Canada, Australia, Poland, Cyprus, UK, Turkey and India. LG Life Sciences, Ltd (‘LGLS’) has also been appointed as the exclusive distributor of ColostrininTM in South Korea subject to import and regulatory approval being obtained. ReGen are currently seeking licensees in other regions of the world (www.regentherapeutics.com).
# MENA countries are : Kuwait, United Arab Emirates, Saudi Arabia, Oman, Bahrain, Qatar, Yemen, Iraq, Iran, Jordan, Syria, Lebanon, Egypt, Sudan, Tunisia, Libya, Algeria and Morocco
For further Information:
Tim Shilton
ReGen Therapeutics Limited
Tim.shilton@regentherapeutics.com
44 – (0)207 153 4920
Rashad Manna
MBM Partners Ltd
rashadmanna@mbmpartners.co.uk
0207 394 6152